Morgan Stanley know nothing ab-To The Moon - Tiger Brokers Online Investing Community - To The Moon

5
1
Favorite

Morgan Stanley know nothing about drugs. Guessing ppl failure

Morgan Stanley Expects Novo Nordisk Alzheimer Trial to Fail as It Slashes Rating

Novo Nordisk was downgraded to underweight by Morgan Stanley.Morgan Stanley analysts say a trial to test whether Novo Nordisk's blockbuster weight-loss drug also will work against Alzheimer's is likely to fail, as it set the most pessimistic target price forecast of any Wall Street bank on the Danish drugmaker.Morgan Stanley cut Novo Nordisk's rating to underweight from equal weight and cut the price target on its U.S.-listed stock to $47 from $59.According to FactSet, only Intron Health has a lower price target, of $46.72.In premarket trade, Novo shares slipped 3% to $53.80.Analysts led by Thibault Boutherin say a trial of semaglutide, the key ingredient in Ozempic and Wegovy, has a 75% chance of not reaching statistical significance in reducing dementia, when results are announced in the coming weeks.They see other problems, too. Weekly prescription data for Ozempic have been declining over the last few month, while weekly prescriptions for Eli Lilly's Mounjaro are growing at a li

Morgan Stanley Expects Novo Nordisk Alzheimer Trial to Fail as It Slashes Rating

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

5

Report

Comment（1）

Top
Latest

DreamZ85
·10-01
Woah Morgan Stanley u give downgrade but you buying more stock?
Reply
Like
Report

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":483929832607864,"tweetId":"483929832607864","gmtCreate":1759139474854,"gmtModify":1759141413198,"author":{"id":3577569919471507,"idStr":"3577569919471507","authorId":3577569919471507,"authorIdStr":"3577569919471507","name":"DreamZ85","avatar":"https://static.tigerbbs.com/4f88a546cd1787f83e30c21f07ed2b3a","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.06.30","exceedPercentage":"60.93%","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>Morgan Stanley know nothing about drugs. Guessing ppl failure</p></body></html>","htmlText":"<html><head></head><body><p>Morgan Stanley know nothing about drugs. Guessing ppl failure</p></body></html>","text":"Morgan Stanley know nothing about drugs. Guessing ppl failure","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/483929832607864","repostId":2571194386,"repostType":2,"repost":{"id":"2571194386","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1759140900,"share":"https://ttm.financial/m/news/2571194386?lang=en_US&edition=fundamental","pubTime":"2025-09-29 18:15","market":"us","language":"en","title":"Morgan Stanley Expects Novo Nordisk Alzheimer Trial to Fail as It Slashes Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2571194386","media":"Dow Jones","summary":"Novo Nordisk was downgraded to underweight by Morgan Stanley.Morgan Stanley analysts say a trial to test whether Novo Nordisk's blockbuster weight-loss drug also will work against Alzheimer's is likely to fail, as it set the most pessimistic target price forecast of any Wall Street bank on the Danish drugmaker.Morgan Stanley cut Novo Nordisk's   rating to underweight from equal weight and cut the price target on its U.S.-listed stock to $47 from $59.According to FactSet, only Intron Health has a lower price target, of $46.72.In premarket trade, Novo shares slipped 3% to $53.80.Analysts led by Thibault Boutherin say a trial of semaglutide, the key ingredient in Ozempic and Wegovy, has a 75% chance of not reaching statistical significance in reducing dementia, when results are announced in the coming weeks.They see other problems, too. Weekly prescription data for Ozempic have been declining over the last few month, while weekly prescriptions for Eli Lilly's  Mounjaro are growing at a li","content":"<html><head></head><body><p style=\"text-align: start;\">Morgan Stanley analysts say a trial to test whether Novo Nordisk’s blockbuster weight-loss drug also will work against Alzheimer’s is likely to fail, as it set the most pessimistic target price forecast of any Wall Street bank on the Danish drugmaker.</p><p style=\"text-align: start;\">Morgan Stanley cut Novo Nordisk’s rating to underweight from equal weight and cut the price target on its U.S.-listed stock to $47 from $59.</p><p>According to FactSet, only Intron Health has a lower price target, of $46.72.</p><p>In premarket trade, Novo shares slipped 3.1% to $53.91.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/c736fdd0c02f513a1d2e710eea0974db\" tg-width=\"536\" tg-height=\"157\"/></p><p style=\"text-align: start;\">Analysts led by Thibault Boutherin say a trial of semaglutide, the key ingredient in Ozempic and Wegovy, has a 75% chance of not reaching statistical significance in reducing dementia, when results are announced in the coming weeks.</p><p style=\"text-align: start;\">That failure should trigger a high single-digit percentage share price decline, they say.</p><p style=\"text-align: start;\">They see other problems, too. Weekly prescription data for Ozempic have been declining over the last few month, while weekly prescriptions for Eli Lilly’s Mounjaro are growing at a linear trajectory.</p><p style=\"text-align: start;\">They’re expecting a 50% cut in price from Medicare Part D for semaglutide and that a head-to-head trial of CagriSema, its next-generation weight-loss drug, versus Lilly’s Zepbound won’t show differentiation.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley Expects Novo Nordisk Alzheimer Trial to Fail as It Slashes Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley Expects Novo Nordisk Alzheimer Trial to Fail as It Slashes Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-09-29 18:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p style=\"text-align: start;\">Morgan Stanley analysts say a trial to test whether Novo Nordisk’s blockbuster weight-loss drug also will work against Alzheimer’s is likely to fail, as it set the most pessimistic target price forecast of any Wall Street bank on the Danish drugmaker.</p><p style=\"text-align: start;\">Morgan Stanley cut Novo Nordisk’s rating to underweight from equal weight and cut the price target on its U.S.-listed stock to $47 from $59.</p><p>According to FactSet, only Intron Health has a lower price target, of $46.72.</p><p>In premarket trade, Novo shares slipped 3.1% to $53.91.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/c736fdd0c02f513a1d2e710eea0974db\" tg-width=\"536\" tg-height=\"157\"/></p><p style=\"text-align: start;\">Analysts led by Thibault Boutherin say a trial of semaglutide, the key ingredient in Ozempic and Wegovy, has a 75% chance of not reaching statistical significance in reducing dementia, when results are announced in the coming weeks.</p><p style=\"text-align: start;\">That failure should trigger a high single-digit percentage share price decline, they say.</p><p style=\"text-align: start;\">They see other problems, too. Weekly prescription data for Ozempic have been declining over the last few month, while weekly prescriptions for Eli Lilly’s Mounjaro are growing at a linear trajectory.</p><p style=\"text-align: start;\">They’re expecting a 50% cut in price from Medicare Part D for semaglutide and that a head-to-head trial of CagriSema, its next-generation weight-loss drug, versus Lilly’s Zepbound won’t show differentiation.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVO":"诺和诺德"},"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2571194386","content_text":"Morgan Stanley analysts say a trial to test whether Novo Nordisk’s blockbuster weight-loss drug also will work against Alzheimer’s is likely to fail, as it set the most pessimistic target price forecast of any Wall Street bank on the Danish drugmaker.Morgan Stanley cut Novo Nordisk’s rating to underweight from equal weight and cut the price target on its U.S.-listed stock to $47 from $59.According to FactSet, only Intron Health has a lower price target, of $46.72.In premarket trade, Novo shares slipped 3.1% to $53.91.Analysts led by Thibault Boutherin say a trial of semaglutide, the key ingredient in Ozempic and Wegovy, has a 75% chance of not reaching statistical significance in reducing dementia, when results are announced in the coming weeks.That failure should trigger a high single-digit percentage share price decline, they say.They see other problems, too. Weekly prescription data for Ozempic have been declining over the last few month, while weekly prescriptions for Eli Lilly’s Mounjaro are growing at a linear trajectory.They’re expecting a 50% cut in price from Medicare Part D for semaglutide and that a head-to-head trial of CagriSema, its next-generation weight-loss drug, versus Lilly’s Zepbound won’t show differentiation.","news_type":1,"symbols_score_info":{"NVO":1.5}},"isVote":1,"tweetType":1,"viewCount":766,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":53,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":484542567920384,"commentId":"484542567920384","gmtCreate":1759326850895,"gmtModify":1759326855611,"authorId":3577569919471507,"author":{"id":3577569919471507,"idStr":"3577569919471507","authorId":3577569919471507,"name":"DreamZ85","avatar":"https://static.tigerbbs.com/4f88a546cd1787f83e30c21f07ed2b3a","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.06.30","exceedPercentage":"60.93%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":483929832607864,"objectIdStr":"483929832607864","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Woah Morgan Stanley u give downgrade but you buying more stock?","text":"Woah Morgan Stanley u give downgrade but you buying more stock?","html":"Woah Morgan Stanley u give downgrade but you buying more stock?","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0}],"hasMoreComment":true,"orderType":2}